Drs. Kato and Gladwin are now recruiting participants for the Multi-Center Study of Riociguat in Sickle Cell Patients trial. For more information, or to see if you qualify, please contact Carolyn Newkirk at 412-692-2437 or can59@pitt.edu.
You can also find information on the ClinicalTrials.gov website, study identifier NCT02633397.
A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases – Full Text View – ClinicalTrials.gov
A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases
